Synchronization and control of linear accelerator, multi-leaf collimator, gantry system, patient support system and x-ray beam generation system at the same time is difficult to establish, particularly with hard real-time requirements. The presented technology comprises a control unit consisting of standardized programmable logic controllers for real-time operation of all subsystems of a radiation therapy device. Thus, the technology allows precise and dynamic patient treatment with high time resolution.
Efficient treatment strategy based on antigen-armed antibodies (AgAbs). After AgAb treatment Epstein-Barr virus-transformed B cell lines and various Burkitt’s lymphoma cell lines were able to present antigens that efficiently induce T cell activation.
Endostatin is an antiangiogenic protein first discovered in Folkman's laboratory at Childrens Hospital, Harvard Medical School, and Boston. The antitumor properties of this protein are well established. Nowever, the amount of protein required for injection in patients was beyond production feasibility due to the poor pharmacokinetics of endostatin monomer. We have shown that the problem of poor pharmacokinetics can be solved by using the Fc domain of IgG being conjugated to endostatin, a component of all monoclonal antibodies approved for patients with a number of diseases including cancer. As a result of employing Fc-endostatin, the half-life in mice was increased to 2 weeks instead of 2 hours for endostatin alone, consistent with pharmacokinetics of monoclonal antibodies.
Labeled oligonucleotides are used in research and for diagnostic, therapeutic and industrial applications. Researchers from the DKFZ and the Heidelberg University developed a fast method for post-synthetic multiple orthogonal labeling of oligonucleotides by combining the inverse Diels-Alder reaction with the well-known copper-catalyzed azide-alkyne cycloaddition.
The here presented technology provides an apparatus for 4Pi STED which allows to generate a three-dimensional light intensity distribution comprising a very steep light intensity gradient between the areas of minimum and maximum light intensity.
This technology was achieved by a cooperation between McGill University and DKFZ. Brain tumours, such as the highly aggressive glioblastoma multiforme (GBM), are currently the leading cause of cancer-related mortality and morbidity in children. Current diagnosis of brain cancers involve MRI, PET and CT scans, angiographies, followed by biopsies performed either during the resection of the tumor or as a separate procedure via a burr hole. A blood-based test would provide a more economical, i.e accessible and less invasive diagnostic tool. The GBM specific biomarker has been patented and is available for licensing i.e. for companion diagnostics.
70-80% of newly diagnosed breast tumors account for hormone receptor positive breast cancer (also known as luminal breast cancer). The histologic grade of luminal breast cancer is often determined by semi-quantitative methods describing morphologic features related to the differentiation states of the tumor specimen. In order to make a clear-cut classification of luminal breast cancer as either “grade 1” (= low risk) or “grade 3” (= high risk) tumors, DKFZ researchers have developed a 3-protein marker set.
The aim of radiation therapy is to eradicate a tumor without causing significant damage to contiguous normal tissue. For precise field shaping of the radiation beam multileaf collimators (MLC) have been broadly established. The linear servo MLC presented here provides various advantages over conventionally employed MLCs like reduced size and weight, dynamic leaf movements up to 4 m/s, direct fixation of the linear servo rod to the associated leaf and position sensors are implemented in the linear drives.
This humanized monoclonal antibody efficiently neutralizes HSV fully in-dependent of complement or immune effector cell recruitment and completely abrogates viral cell-to-cell spread, a key mechanism by which HSV escapes humoral immune surveillance.
The invention presents a new method for pseudonymizing e.g. patient identifiers in which the pseudonymmization service provider is unable to derive the patient identifier from the pseudonym, but rather this ability is assigned to an authorized third party (Ombudsman). This is achieved by asymmetric and symmetric encryption algorithms and key derivation functions in combination with a new algorithm to pseudonymize a patient identifier. The asymmetric and symmetric encryption algorithms used in the pseudonymization software are approved by the technical directive TR-03116 for eCard-Projects of the German Federal Government. The method/software can be used for pseudonymmization of any sensitive data if they are processed by third-party institutions e.g. patient samples for translational research or bank account data.
Numerous studies have shown that selective inhibition of the MetAP-II subtype halts the growth of endothelial cells in culture, inhibits angiogenesis in animal models, and is a validated strategy for anti-angiogenic cancer therapy. In addition, MetAP-II has also emerged as a promising target for other indications, including malaria, rheumatoid arthritis, pulmonary hypertension, and obesity. So the invention describes the design of the small molecules which was guided by the chemical structure of fumagillin. The substances have drug-like substructures, exist in novel chemical space, and the active enantiomeric series has been identified. In addition data on solubility and in vitro plasma half life time are available.
Combination therapy of wogonin or rocaglamide together with Bcl-2 inhibitors leads to increased efficacy of ABT-263, even in cancer cells which have acquired resistance to ABT-263, and without affecting proliferation of normal T cells and platelets.
The assembly and maintenance of functional nucleoli is essential for cell viability. DKFZ researchers developed anti-sense oligos that target Alu element-containing RNAs, which are essential for intact nucleoli, for cancer cell specific induction of apoptosis.
The antibody recognizes the kinase HIPK2 only when phosphorylated at Thr880 and Ser882 and therefore can be used for predicting kinase activity.
The invention discloses a measles virus based oncolytic tumor therapy. The virus encodes antibodies against CTLA-4 or PD-L1 and has proven effectiveness in a in vivo mouse tumor model.
The present invention discloses an antibody which selectively binds SITR1 dependent on its activation status.
Feedback
